Volume 6, Issue 1 (2020)                   Pharm Biomed Res 2020, 6(1): 53-60 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hosseini S A, Ahmadipour A, Soltani M, Mehdipour M, Mandegary A, Karami-Mohajeri S. Malathion-increased Hepatotoxicity in Diabetic Rats. Pharm Biomed Res 2020; 6 (1) :53-60
URL: http://pbr.mazums.ac.ir/article-1-280-en.html
1- Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
2- Department of Pharmacology & Toxicology, School of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran.
Abstract:   (2137 Views)
Background: Malathion (MT), an organophosphorus pesticide, induces hepatotoxicity and is associated with hyperglycemia and the development of diabetes mellitus. 
Objectives: This study was aimed to evaluate the effects of sub-acute exposure to sub-lethal dose of MT in the liver of diabetic rats. 
Methods: Non-diabetic and streptozotocin-induced diabetic rats received MT at a dose of 150 mg/kg/day orally. After 28 days, fasting blood glucose, Glucose Tolerance Test (GTT), serum aminotransferases, and liver histopathology and antioxidant status were examined. 
Results: MT impaired GTT, caused alteration in histopathology of histopathology and antioxidant status of liver in non-diabetic rats. Impairment in GTT did not observe in diabetic rats exposed to MT, but histopathology changes and antioxidant status alteration was more severe.
Conclusion: Repeated sub-lethal dose of MT exacerbated hepatotoxicity in diabetes condition through further impairment in the antioxidant defense system. 
Full-Text [PDF 2858 kb]   (1461 Downloads) |   |   Full-Text (HTML)  (1410 Views)  
Type of Study: Original Research | Subject: Toxicology

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Pharmaceutical and Biomedical Research

Designed & Developed by : Yektaweb